CLINICAL TRIALS PROFILE FOR ACETAZOLAMIDE
✉ Email this page to a colleague
All Clinical Trials for acetazolamide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000115 ↗ | Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema | Completed | National Eye Institute (NEI) | Phase 2 | 1990-12-01 | To test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid macular edema. |
| NCT00004802 ↗ | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders | Completed | Ohio State University | Phase 3 | 1992-06-01 | OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis. |
| NCT00004802 ↗ | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders | Completed | National Center for Research Resources (NCRR) | Phase 3 | 1992-06-01 | OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis. |
| NCT00108602 ↗ | Sleep Apnea: Mechanism and Cerebrovascular Consequences | Withdrawn | US Department of Veterans Affairs | N/A | 2007-05-01 | This study will determine the effect of ventilatory stimulation on obstructive sleep apnea in selected patients with stroke. We will select a subset of patients with stroke in the prior 3 months who are most likely to have ventilatory instability as a cause of the upper airway obstruction as indicated by the absence of obesity, an abnormal hypocapnic apnea threshold and resolution of obstructive apnea during CO2 administration. Following baseline polysomnography, patients will be randomly assigned to acetazolamide (250 mg hs [at bedtime]) versus placebo for 7 days. Polysomnography will be repeated and then subjects will cross-over therapies for another 7 days followed by a final nocturnal polysomnography. |
| NCT00108602 ↗ | Sleep Apnea: Mechanism and Cerebrovascular Consequences | Withdrawn | VA Office of Research and Development | N/A | 2007-05-01 | This study will determine the effect of ventilatory stimulation on obstructive sleep apnea in selected patients with stroke. We will select a subset of patients with stroke in the prior 3 months who are most likely to have ventilatory instability as a cause of the upper airway obstruction as indicated by the absence of obesity, an abnormal hypocapnic apnea threshold and resolution of obstructive apnea during CO2 administration. Following baseline polysomnography, patients will be randomly assigned to acetazolamide (250 mg hs [at bedtime]) versus placebo for 7 days. Polysomnography will be repeated and then subjects will cross-over therapies for another 7 days followed by a final nocturnal polysomnography. |
| NCT00120731 ↗ | Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones | Withdrawn | Children's Mercy Hospital Kansas City | N/A | 2005-07-01 | High amounts of calcium in the urine (hypercalciuria) can cause development of kidney stones in children. Treatment for these children includes plenty of fluids, a low-salt diet and medications such as potassium citrate. A major advantage of potassium citrate, as compared to hydrochlorothiazide, is its lack of side effects. One problem the researchers and others have observed is that some children continue to form kidney stones despite correction of hypercalciuria with potassium citrate. One possible explanation is that in some individuals potassium citrate therapy results in an excessive elevation of urine pH, a situation that may predispose to calcium phosphate stone formation. In this study, the researchers will study the effects of potassium citrate on urine chemistries and acid-base balance in three groups of children aged 5-17 years: - children who are hypercalciuric stone formers; - healthy children without a history of hypercalciuria or kidney stones. Particular attention will be paid to try to identify those who develop a very high urine pH (>8) and the factors leading to this metabolic reaction. The researchers will try to learn whether it is the child's characteristics, the disease manifestations, the dose of the drug, or a combination of the above which may be the cause of the development of very alkaline urine. Based on the results, the researchers hope to be able to better "tailor" the individual treatment for each child with kidney stones. |
| NCT00222534 ↗ | Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis | Completed | University of Oslo School of Pharmacy | Phase 4 | 2002-01-01 | Respiratory failure is a common consequence of chronic obstructive pulmonary disease (COPD). A concurrent metabolic alkalosis may worsen the respiratory failure, as a higher pH in blood (and thus in cerebrospinal fluid) results in a weaker respiratory drive. Use of diuretics is the most common cause of metabolic alkalosis. When a patient with an acute exacerbation of a respiratory failure is also alkalotic, there are (at least theoretical) reasons to lower the pH in order to increase the respiratory drive. Among other alternatives, the drug acetazolamide can be used for this purpose. In some hospitals there is a tradition for the use of acetazolamide on this indication, but any evidence for the effect of such a treatment is rather weak. Thus, the aim of this trial is to evaluate the effect of acetazolamide as an adjuvant treatment for hospitalized patients with acute exacerbation of respiratory failure in combination with metabolic alkalosis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for acetazolamide
Condition Name
Clinical Trial Locations for acetazolamide
Trials by Country
Clinical Trial Progress for acetazolamide
Clinical Trial Phase
Clinical Trial Sponsors for acetazolamide
Sponsor Name
| Sponsor Name for acetazolamide | |
| Sponsor | Trials |
| University of Zurich | 23 |
| National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov | 16 |
| University of California, San Diego | 5 |
| [disabled in preview] | 17 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
